The FDA authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original shot.
The U.S. Food and Drug Administration authorized Pfizer's omicron booster shot for kids younger than five who were previously vaccinated with three doses of the company's original vaccine.
Children six months through four years old who completed their three-dose primary series with Pfizer and BioNTech's original monovalent shots more than two months ago are now eligible to receive a single booster dose of the updated shot. The new shot is bivalent, meaning it targets the original Covid strain as well as omicron BA.4 and BA.5.
The new authorization is for young children who completed their three doses before the new shot was available.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
FDA Approves Fast-Acting Nasal Spray for Migraines, Pfizer SaysClinical trials showed the nasal spray provided migraine relief within 15-30 minutes of use, with the relief lasting up to 48 hours in many patients.
Consulte Mais informação »
Pfizer receives FDA approval for migraine nasal spray, claims pain relief in 15 minutesThe drug, Zavzpret, also known as zavegepant, was approved on Thursday for the treatment of acute migraines with or without an aura in adults.
Consulte Mais informação »
FDA: Paxlovid Does Not Cause COVID ‘Rebound’The FDA says in a new report that rebound also occurs in people who did not take paxlovid—which can prevent COVID from becoming severe if given early enough—and appears to be part of the disease process in some.
Consulte Mais informação »
FDA: Paxlovid not associated with COVID reboundPaxlovid isn't associated with COVID rebound, in which patients test positive or have symptoms days after a course of the drug is completed, Food and Drug Administration staff said Tuesday.
Consulte Mais informação »
Pfizer looks beyond COVID sales with $43 bln deal for cancer drugmaker SeagenPfizer Inc on Monday struck a roughly $43 billion deal for Seagen Inc to bulk up its cancer treatment portfolio, as the drugmaker braces for a steep fall in COVID-19 product sales and loss of exclusivity for some top sellers.
Consulte Mais informação »
Pfizer looks past COVID with $43 bln deal for cancer drug innovator SeagenPfizer Inc struck a $43 billion deal for Seagen Inc to add innovative targeted therapies to its portfolio of cancer treatments as it braces for a steep fall in COVID-19 product sales and stiff competition for some top sellers.
Consulte Mais informação »